CF PharmTech (HKG:2652) said it expects 2 million yuan to 3 million yuan in attributable profit for 2025, down from 21.1 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Shares of the pharmaceutical firm fell nearly 2% in late morning trade Monday.
The drop in profit comes amid an expected decline in revenue to 410 million yuan to 450 million yuan from 607.8 million yuan in 2024.
The company's financial results are due by the end of March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments